WO2001007025A3 - Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines - Google Patents
Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines Download PDFInfo
- Publication number
- WO2001007025A3 WO2001007025A3 PCT/US2000/016320 US0016320W WO0107025A3 WO 2001007025 A3 WO2001007025 A3 WO 2001007025A3 US 0016320 W US0016320 W US 0016320W WO 0107025 A3 WO0107025 A3 WO 0107025A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- cardiac abnormalities
- propanolamines
- aryloxy
- aryloxy propanolamines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60495/00A AU6049500A (en) | 1999-07-22 | 2000-07-11 | Treatment of cardiac abnormalities with aryloxy propanolamines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14517499P | 1999-07-22 | 1999-07-22 | |
US60/145,174 | 1999-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001007025A2 WO2001007025A2 (fr) | 2001-02-01 |
WO2001007025A3 true WO2001007025A3 (fr) | 2002-01-17 |
Family
ID=22511930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/016320 WO2001007025A2 (fr) | 1999-07-22 | 2000-07-11 | Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6049500A (fr) |
WO (1) | WO2001007025A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6050000A (en) * | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
WO2005102304A1 (fr) * | 2004-04-23 | 2005-11-03 | Northern Sydney And Central Coast Area Health Service | Methodes et compositions de traitement d'etats myocardiques |
EP1947103A1 (fr) * | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, procédés de préparation correspondant et utilisation d'aryloxypropanolamines en tant que médicaments |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611003A1 (fr) * | 1993-02-09 | 1994-08-17 | Merck & Co. Inc. | Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité |
EP0764640A1 (fr) * | 1995-09-21 | 1997-03-26 | Eli Lilly And Company | Agonistes adrénergiques bêta-3 spécifiques |
EP0827746A1 (fr) * | 1996-09-05 | 1998-03-11 | Eli Lilly And Company | Analogues de carbazole étant agonistes B3-adrénergiques sélectifs |
WO1999029672A1 (fr) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | AGONISTES β3-ADRENERGIQUES SPECIFIQUES |
WO2001007026A2 (fr) * | 1999-07-22 | 2001-02-01 | Eli Lilly And Company | Methode de traitement amelioree du diabete de type ii et de l'obesite |
-
2000
- 2000-07-11 WO PCT/US2000/016320 patent/WO2001007025A2/fr active Application Filing
- 2000-07-11 AU AU60495/00A patent/AU6049500A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611003A1 (fr) * | 1993-02-09 | 1994-08-17 | Merck & Co. Inc. | Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité |
EP0764640A1 (fr) * | 1995-09-21 | 1997-03-26 | Eli Lilly And Company | Agonistes adrénergiques bêta-3 spécifiques |
US5786356A (en) * | 1995-09-21 | 1998-07-28 | Eli Lilly And Company | Selective β3 adrenergic agonists |
EP0827746A1 (fr) * | 1996-09-05 | 1998-03-11 | Eli Lilly And Company | Analogues de carbazole étant agonistes B3-adrénergiques sélectifs |
WO1999029672A1 (fr) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | AGONISTES β3-ADRENERGIQUES SPECIFIQUES |
WO2001007026A2 (fr) * | 1999-07-22 | 2001-02-01 | Eli Lilly And Company | Methode de traitement amelioree du diabete de type ii et de l'obesite |
Non-Patent Citations (4)
Title |
---|
CANDELORE, MARI RIOS ET AL: "Potent and selective human.beta.3-adrenergic receptor antagonists", J. PHARMACOL. EXP. THER. (1999), 290(2), 649-655, 1999, XP001031847 * |
COHEN M L ET AL: "ARYL PROPANOLAMINES: COMPARISON OF ACTIVITY AT HUMAN BETA3 RECEPTORS, RAT BETA3 RECEPTORS AND RAT ATRIAL RECEPTORS MEDIATING TACHYCARDIA", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 126, no. 4, 1999, pages 1018 - 1024, XP001015387, ISSN: 0007-1188 * |
WEBER A E ET AL: "3-pyridyloxypropanolamine agonists of the beta3 adrenergic receptor with improved pharmacokinetic properties", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 16, 18 August 1998 (1998-08-18), pages 2111 - 2116, XP004137229, ISSN: 0960-894X * |
WEBER A E ET AL: "Potent, selective benzenesulfonamide agonists of the human beta3 adrenergic receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 9, 1 May 1998 (1998-05-01), pages 1101 - 1106, XP004137028, ISSN: 0960-894X * |
Also Published As
Publication number | Publication date |
---|---|
WO2001007025A2 (fr) | 2001-02-01 |
AU6049500A (en) | 2001-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5032500A (en) | Treatment of irregular ventricular contractions | |
HK1023064A1 (en) | Method of inhibiting bacterial or fungal growth using a complexing agent | |
WO2002053101A3 (fr) | Procede de traitement de troubles fibrogenes et autres symptomes de type ivc | |
CA2140106A1 (fr) | Methode de traitement des affections vasculaires hyperproliferatives | |
WO2003020202A3 (fr) | Methode permettant de reduire l'hypertension et l'insuffisance cardiaque | |
AU3920900A (en) | Compounds and methods to treat cardiac failure and other disorders | |
WO2002019966A3 (fr) | Procedes de traitement de l'arrhythmie cardiaque | |
AU2002218742A1 (en) | Application of photochemotherapy for the treatment of cardiac arrhythmias | |
AU2001249881A1 (en) | Method of treating the heart | |
EP1266658A3 (fr) | Utilisation de dérivés de l'acide bétulinique pour le traitement et la prévention du mélanome | |
WO2001064676A3 (fr) | INHIBITEURS DE LA P38-α KINASE | |
WO2000059487A3 (fr) | Utilisation de flupirtine pour le traitement de la fibromyalgie et d'affections associees a la fibromyalgie | |
EP1126855A4 (fr) | Methodes pour la prevention/le traitement des cellules auditives ciliees et neurones cochleaires endommages | |
WO2001058891A3 (fr) | Derives de piperazine et de piperidine | |
PL310476A1 (en) | Application of lamotrigin in treating neuro-aids diseases | |
CA2388939A1 (fr) | Traitements therapeutiques pour des deficiences en cellules sanguines | |
SE0104248D0 (sv) | Method of treatment | |
EP1889614A3 (fr) | Procédés d'utilisation d'inhibiteurs de récapture de la sérotonine sélective à départ rapide pour le traitement de dysfonctionnements sexuels | |
CA2134347A1 (fr) | Derives du thiazole ou de l'imidazole utilises comme inhibiteurs de la reaction de maillard | |
AU4385399A (en) | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | |
WO2001007026A3 (fr) | Methode de traitement amelioree du diabete de type ii et de l'obesite | |
WO2001010427A3 (fr) | Utilisation topique d'agents anti-muscarinique | |
WO2002096362A3 (fr) | Methode de traitement de maladies fibreuses ou d'autres indications | |
MY133785A (en) | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | |
WO2005062958A3 (fr) | Procedes d'utilisation des genes hcn pour le traitement d'arythmies cardiaques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |